Braveheart Bio
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Braveheart Bio (BRVE) | 1.83B | -27.82 | 3.68 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 31.7% below Morningstar's fair value estimate.
Fair value
Braveheart Bio Inc is assigned a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 27% discount to our quantitative fair value estimate of $26.85 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's valuation metrics bolster our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 9.3 ranks in the top 45% globally. While the liquidation value can be important for some businesses, we don't believe this is one of them. The low cash balance relative to the firm's market value could signal heavy reinvestment for growth. We believe this is a sign that shares could be cheap.
On a different note, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, falls in the top 40% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Braveheart Bio discussion 0 comments